Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Effet de la morphine peropératoire sur la douleur postopératoire après un pontage aortocoronarien

5 novembre 2026 mis à jour par: Yasemin Ozsahin, Istanbul University - Cerrahpasa

L'Effet de l'Utilisation de Morphine Peropératoire sur la Douleur Postopératoire dans la Chirurgie de Pontage Aortocoronarien : Un Essai Clinique Randomisé et Contrôlé

Ethics committee approval was obtained for this study, which was planned as a prospective, randomized, controlled, single-center trial to be conducted in patients undergoing coronary artery bypass grafting (CABG) surgery between December 2025 and March 2026.

Patients eligible for inclusion were randomized into two groups at a 1:1 ratio using a random number list generated via the random.org website. Randomization was performed by an independent investigator who was not involved in the study procedures. The allocation sequence was placed into sequentially numbered, opaque, sealed envelopes. Upon enrollment of each patient, the next numbered envelope was opened to determine group assignment.

Patients who did not complete the study protocol or did not receive the allocated medication were excluded from the analysis, and a per-protocol analysis approach was applied. The randomization list was kept confidential and was accessible only to authorized statistical personnel. Patients were followed in two groups: the Control Group (Group C) and the Morphine Group (Group M).

All procedures were performed at the Istanbul University-Cerrahpaşa Cardiology Institute. After obtaining written informed consent, all patients were transferred to the operating room, where an 18G intravenous cannula was inserted, followed by premedication with midazolam 0.03 mg/kg (IV).

Standard monitoring included 5-lead electrocardiography (ECG), heart rate measurement, invasive arterial blood pressure monitoring, and peripheral oxygen saturation assessment. Anesthesia induction was standardized for all patients using midazolam 0.15 mg/kg, fentanyl 10 µg/kg, and rocuronium 0.6 mg/kg (IV). Orotracheal intubation was performed using an endotracheal tube of appropriate size according to the patient's age and sex.

Following intubation, mechanical ventilation was initiated and adjusted to maintain end-tidal carbon dioxide (EtCO₂) levels between 35 and 45 mmHg. Anesthesia maintenance was achieved using a total intravenous anesthesia (TIVA) technique with continuous infusions of propofol (1-10 mg/kg/h), fentanyl (2-4 µg/kg/h), and rocuronium (20 mg/h), targeting a bispectral index (BIS) value between 40 and 60. Prior to surgical incision, patients in the Morphine Group (Group M) received 5 mg intravenous morphine, administered with careful consideration of their hemodynamic status.

During surgery, all patients were placed on cardiopulmonary bypass (CPB). After completion of graft anastomoses and stabilization of vital signs, patients were weaned from CPB. At this stage, patients in Group M received an additional 5 mg intravenous morphine. In contrast, patients in the Control Group (Group K) continued to receive perioperative fentanyl infusion.

Postoperatively, patients were transferred to the intensive care unit (ICU) while intubated and mechanically ventilated. Extubation was performed according to clinical criteria. In the ICU, all patients received intravenous paracetamol 1000 mg every 6 hours and tramadol 100 mg intravenously. Pain intensity was assessed using the Numerical Rating Scale (NRS) / Visual Analog Scale (VAS). If the pain score exceeded 4, 3 mg intravenous morphine was administered, and total morphine consumption was recorded.

Preoperative variables collected included age, sex, height, weight, body mass index (BMI), and American Society of Anesthesiologists Physical Status (ASA PS) classification. Intraoperative variables included administered drug doses, duration of surgery, cardiopulmonary bypass time, and total anesthesia duration.

In the postoperative period, the duration of mechanical ventilation in the intensive care unit (ICU), the presence of nausea and vomiting, postoperative ileus, and respiratory depression will be recorded. In addition, pain intensity at the thoracic tube insertion site, sternum, and saphenous vein graft incision will be assessed at the 1st, 2nd, 4th, 8th, and 24th hours following extubation using the Numerical Rating Scale (NRS) / Visual Analog Scale (VAS). All pain assessments will be performed and recorded by a blinded observer. Pain associated with the urinary catheter will also be evaluated using the NRS.

Prolonged postoperative ileus will be defined as the presence of abdominal distension and absence of bowel sounds in a patient without mechanical intestinal obstruction who experiences nausea or vomiting and fails to pass flatus or stool for more than three postoperative days. The severity and frequency of postoperative nausea and vomiting (PONV) will be assessed. Respiratory depression will be defined as a suppressed ventilatory response to hypercapnia or hypoxemia.

Aperçu de l'étude

Description détaillée

Pain intensity at the thoracic tube insertion site, sternum, and saphenous vein graft incision will be assessed at the 1st, 2nd, 4th, 8th, and 24th hours following extubation using the Numerical Rating Scale (NRS) / Visual Analog Scale (VAS).

Type d'étude

Interventionnel

Inscription (Réel)

80

Phase

  • Phase 4

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Outside of the US
      • Istanbul, Outside of the US, Turquie (Türkiye), 34000
        • Istanbul University -Cerrahpasa Institute of Cardiology

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 80 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • patients aged 18 to 80 years
  • classified as American Society of Anesthesiologists (ASA) III
  • who are scheduled for elective coronary artery bypass grafting.

Exclusion Criteria:

  • Chronic opioid use.
  • Severe liver or kidney disease.
  • History of alcohol or substance abuse.
  • Left ventricular ejection fraction below 40%.
  • Inability to be weaned from mechanical ventilation within 12 hours after completion of surgery.
  • Undergoing combined cardiac surgery, including valve procedures.
  • Requirement for intra-aortic balloon pump (IABP) support.
  • Surgery performed on a beating heart.
  • Emergency surgery.
  • Reoperation due to bleeding or other complications.
  • Refusal to participate in the study.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Aucune intervention: Group C (control group)

Patients in this group received a standard fentanyl infusion during the entire CABG procedure until they were transferred out of the operating room."

Expérimental: Group M (group morphine)

Patients in this group received 5 mg of morphine prior to the initiation of the surgical procedure and an additional 5 mg at the time of separation from cardiopulmonary bypass.

Unlike previous studies, this study aims to evaluate the postoperative effects of morphine administered intraoperatively rather than postoperative morphine administration

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
VAS Level
Délai: 1st, 2nd, 4th, 8th, and 24th hours after extubation.

Pain scores at the thoracic tube insertion site, sternum, and saphenous graft incision will be assessed using a visual analog scale (VAS) by a blinded observer. The VAS consists of a 10-cm horizontal line anchored by two descriptors: "no pain" at the left end (0) and "worst imaginable pain" at the right end (10). Patients are asked to mark the point on the line that best represents their perceived level of pain at the time of assessment. The distance from the left end of the line to the patient's mark is measured in centimeters and recorded as the VAS score, ranging from 0 to 10.

0: No pain

1-3: Mild pain

4-6: Moderate pain

7-10: Severe pain

1st, 2nd, 4th, 8th, and 24th hours after extubation.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
PONV
Délai: 1st, 2nd, 4th, 8th, and 24th hours after extubation

The secondary objective is to assess, the incidence of nausea and vomiting (PONV)(side effect of morphine). The severity and frequency of PONV will be assessed. PONV will be graded as follows: None: No nausea, Mild nausea, a single episode of vomiting, nausea triggered by external stim, Moderate: Two episodes of vomiting, nausea without external stimulus, and need for a single dose of antiemetic, Severe nausea, more than two episodes of vomiting, and requirement for multiple doses of antiemetics

1st, 2nd, 4th, 8th, and 24th hours after extubation

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 février 2026

Achèvement primaire (Réel)

26 juin 2026

Achèvement de l'étude (Réel)

11 septembre 2026

Dates d'inscription aux études

Première soumission

6 février 2026

Première soumission répondant aux critères de contrôle qualité

13 mars 2026

Première publication (Réel)

16 mars 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

6 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

5 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner